Mechanism of Action of"Epimedium-Angelica"in the Treatment of Asteoporosis Based on the Analysis of Network Pharmacology
Objective To explore the active components and mechanism of"Epimedium-Angeli-ca"in the treatment of osteoporosis(OP).Methods The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)was utilized to obtain the active ingre-dients and the corresponding predicted targets of"Epimedium-Angelica".The target genes of OP were obtained from five databases:GeneCards,OMIM,PharmGkb,TTD,and DrugBank.The genes obtained from the above five databases were combined and intersected.Then the poten-tial targets of"Epimedium-Angelica"and OP were intersected to obtain the"drug-disease"common targets.The Venny 2.1.0 mapping tool was used to find out the mapping and draw the venn diagram.Protein-protein interac-tion(PPI)was established by String 11.5 database.The relevant data analysis network was constructed by Cytoscape 3.9.1 software to screen the core target genes.Finally,the key target genes were enriched and analyzed using the DAVID2021 da-tabase,and the analyzed target gene data were visualized and mapped for GO and Kyoto Ency-clopedia of Genes and Genomes(KEGG)pathways using the Microbiotics online mapping soft-ware.ResultThe Epimedium-Angelica drug pairs involved 24 major chemical components and 129 protein targets,1159 genes associated to osteoporosis.After mapping,74 common targets of drugs and diseases were obtained.PPI analysis revealed that interleukin-1B(interleukin-1B,IL-1B),JUN,filament/threonine protein kinase AKT 1(AKT 1)may be the core targets of"Epimedium-Angelica"drugs for the treatment of OP.GO enrichment analysis suggests that bio-logical processes mainly include the positive regulation of RNA polymerase Ⅱ promoter transcrip-tion and the positive regulation of gene expression.KEGG pathway enrichment analysis suggested that the effects of"Epimedium-Angelica"in the treatment of osteoporosis mainly focused on advanced glycation end product-receptor(AGE-RAGE),phosphatidylinositol 3 kinase/protein kinase B(PI3K-Akt),mitogen-activated protein kinase(mitogen-activated protein kinase,MAPK),interleukins-17(Interleukin-17,L-17)and other signaling pathways.Conclusion The compatibility of Epimedium-Angelica can treat osteoporosis through multiple ways and targets.
network pharmacologyosteoporosisEpimediumAngelicamechanism of action
NETL
NSTL
万方数据
